Want to see IMRN full AI Analyst Report?
IMRN Stock Chart & Stats
$1.16
-$0.05(-4.50%)
At close: 4:00 PM EDT
$1.16
-$0.05(-4.50%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous Close$1.06
Volume36.17K
Average Volume (3M)18.73K
Market Cap
$8.62M
Enterprise Value-$1.44
Total Cash (Recent Filing)$9.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding8,071,202
10 Day Avg. Volume14,118
30 Day Avg. Volume18,727
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.04
Price to Sales (P/S)1.51
P/FCF Ratio-3.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$6.43M
Bulls Say, Bears Say
Bulls Say
Commercialization TractionThe substantial multi-year revenue expansion shows that Immuron has moved beyond a purely developmental model. Continued sales of Travelan and other gastrointestinal products provide commercial validation and a foundation for future channel growth.
Solid Gross MarginA gross margin near 64% indicates that product economics are not the primary constraint on performance. If revenue scales through distributors and retail channels, this margin profile could support better operating leverage over time.
Debt-Free Balance SheetThe absence of debt limits refinancing pressure and interest obligations, preserving financial flexibility for product commercialization and clinical development. Meaningful equity and assets also provide a cushion while management works toward sustainable profitability.
Bears Say
Persistent Operating LossesImmuron remains materially unprofitable despite its commercial revenue base and solid gross margin. Persistent operating losses indicate that research, development, and corporate costs continue to exceed gross profit, delaying self-funded growth.
Negative Cash GenerationOngoing negative operating and free cash flow means the business is not yet funding its activities internally. Unless cash generation improves, Immuron may require additional capital to sustain clinical programs and commercial expansion.
Recent Revenue VolatilityThe latest revenue contraction weakens confidence in a smooth path toward profitability and suggests demand, distribution, or product execution remains uneven. Sustained volatility could limit operating leverage and make funding needs harder to forecast.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $8.62M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 168 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Aug 27, 2026. The company reported -$0.166 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.162.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,071,202 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.166 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went down -1.288%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors